Target sets opening date, preps new look for Bridgehampton store replacing Kmart
Target is opening a new store in Bridgehampton on October 11, replacing a Kmart that closed in 2024. The store features a unique design tailored to the Hamptons' aesthetic, including a white logo and gray bollards instead of the traditional red, to comply with local zoning and community expectations. This 91,036-square-foot store, smaller than typical Targets but not a small-format, will be the company's farthest east on Long Island and aims to fill a retail void in the area.
Sumitomo Life Insurance Co. Takes $1.56 Million Position in CVS Health Corporation $CVS
Sumitomo Life Insurance Co. has acquired a new position in CVS Health Corporation, purchasing 15,126 shares valued at approximately $1.56 million in the second quarter. Other institutional investors also made significant buys, bringing total institutional ownership to 80.66%. Analysts maintain a "Moderate Buy" rating for CVS, with an average price target of $107.17, following strong quarterly earnings that surpassed estimates.
Korea Investment CORP Makes New $97.59 Million Investment in CVS Health Corporation $CVS
Korea Investment CORP has acquired a new stake of 943,358 shares in CVS Health Corporation, valued at approximately $97.59 million during the second quarter. Other institutional investors like Handelsbanken Fonder AB, State Street Corp, Legal & General Group Plc, and Deutsche Bank AG have also adjusted their holdings in CVS. The company reported strong Q2 earnings, beating analyst expectations, and announced a quarterly dividend, with analysts maintaining a "Moderate Buy" consensus rating for the stock.
West Family Investments Inc. Takes Position in CVS Health Corporation $CVS
West Family Investments Inc. has acquired a new position in CVS Health Corporation, purchasing 22,696 shares valued at approximately $176,000. Other institutional investors also adjusted their holdings in CVS, which saw its stock price open at $93.01 and reported strong quarterly earnings of $2.58 EPS, beating analyst estimates, with a revenue increase of 7.3%. Analysts maintain a "Moderate Buy" consensus for CVS Health, with an average price target of $107.17, and the company pays a quarterly dividend yielding about 2.9%.
Callan Family Office LLC Acquires New Shares in CVS Health Corporation $CVS
Callan Family Office LLC has acquired 164,995 shares of CVS Health Corporation, valued at approximately $17.1 million, during the second quarter. Other institutional investors also increased their stakes, bringing total institutional ownership to 80.66%. CVS Health recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, and analysts maintain an average "Moderate Buy" rating with a target price of $107.17.
EP Wealth Advisors LLC Buys Shares of 74,542 CVS Health Corporation $CVS
EP Wealth Advisors LLC recently acquired 74,542 shares of CVS Health Corporation, valued at approximately $7.71 million, according to its SEC filing. Other major institutional investors like BlackRock Inc., Vanguard Group Inc., and State Street Corp also significantly modified their holdings in CVS. The company reported strong Q2 earnings, exceeding analyst expectations, and has an annualized dividend of $2.66 with a 2.9% yield.
CVS Health stock holds in the low $90s after Q2 beat
CVS Health (CVS) stock is trading in the low $90s after reporting strong Q2 2026 results, with EPS of $2.58 and revenue of $106.1 billion, surpassing analyst expectations. The company reaffirmed its full-year 2026 EPS guidance of $7.90 to $8.10. Despite the positive earnings beat, investors are closely watching how CVS will achieve its remaining profit targets for the year.
Allworth Financial LP Invests $3.44 Million in CVS Health Corporation $CVS
Allworth Financial LP has acquired a new stake worth approximately $3.44 million in CVS Health Corporation, purchasing 33,215 shares during the second quarter. This move is part of a broader trend, as other institutional investors like BlackRock Inc. and Norges Bank have also significantly increased their holdings in CVS. The article details CVS Health's recent financial performance, including strong quarterly earnings, dividend declaration, and positive ratings from several Wall Street analysts.
How cost and perception could reshape the GLP-1 market
The GLP-1 weight loss drug market is intensely competitive, with Eli Lilly and Novo Nordisk vying for dominance. While drug performance and supply-side strategies are crucial, new surveys indicate that affordability, physician preferences, and patient perceptions significantly influence market share. High costs and social stigma pose challenges, suggesting that success will depend not only on drug efficacy but also on how these medications are viewed and made accessible to patients.
ARS Pharmaceuticals, Inc. (SPRY) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before October 5, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made false and misleading statements regarding the expanded insurance coverage for neffy through CVS Caremark. The company's stock price declined by over 23.9% after announcing that the expanded coverage would not be in place by the guided July 1, 2026 deadline.
CVS Health: Every Community Deserves a Healthier Heart
CVS Health emphasizes that heart disease disproportionately affects various communities, necessitating community-specific solutions. The company advocates for combining accessible care with education, engagement, and social support to improve heart health outcomes. Dr. Ayo Gathing of CVS Health highlights the importance of understanding and addressing the unique barriers faced by Medicaid members, Medicare beneficiaries, and rural populations in preventing and managing cardiovascular disease.
Mystic Asset Management Inc. Purchases New Stake in CVS Health Corporation $CVS
Mystic Asset Management Inc. has acquired a new position in CVS Health Corporation, purchasing over 30,000 shares valued at approximately $3.14 million. This move comes as other institutional investors have also adjusted their stakes in CVS Health, and analysts have recently issued "buy" and "overweight" ratings with increased price targets for the company. CVS Health recently reported strong quarterly earnings, exceeding consensus estimates, and announced a quarterly dividend.
9,013,571 Shares in CVS Health Corporation $CVS Purchased by Bank of New York Mellon Corp
Bank of New York Mellon Corp has acquired a new stake of 9,013,571 shares in CVS Health Corporation, valued at approximately $932.45 million, making them a significant institutional holder. Other major institutional investors like Vanguard Group Inc., State Street Corp, Capital International Investors, Norges Bank, and Morgan Stanley also increased their holdings in CVS Health during the fourth quarter. The article also provides details on CVS Health's recent earnings, dividend announcement, and current analyst ratings, which reflect a consensus "Moderate Buy" rating with an average target price of $107.17.
Advisors Capital Management LLC Acquires New Shares in CVS Health Corporation $CVS
Advisors Capital Management LLC has purchased a new stake of 268,386 shares in CVS Health Corporation, valued at approximately $27.77 million, during the second quarter. Other institutional investors like Sei Investments Co., The Manufacturers Life Insurance Company, and Alliancebernstein L.P. also increased their holdings in CVS Health. The company recently reported strong quarterly earnings, surpassing analyst estimates, and declared a quarterly dividend of $0.665.
Via Transportation's Chief Legal Officer Matthew Levine Awarded 159,872 RSUs
Matthew Levine, Chief Legal Officer of Via Transportation, Inc., was awarded 159,872 restricted stock units (RSUs) of Class A Common Stock on August 18, 2026, at no cost. These RSUs represent a contingent right to receive one share of Class A Common Stock each, with vesting occurring in installments starting July 27, 2027, and continuing quarterly, subject to his continuous service. Post-transaction, Levine holds direct beneficial ownership of 159,872 shares.
Earnings call transcript: NovaBridge Biosciences shares fall on q2 2026 update
NovaBridge Biosciences reported ending Q2 2026 with $216 million in cash and investments, highlighting progress in its oncology (givastomig) and ophthalmology (VIS-101) pipelines. Despite positive clinical data, including Fast Track status for givastomig, the stock fell 8.59% in premarket trading as the company, a clinical-stage biotech, did not report revenue or earnings per share. Management reiterated that current funds are sufficient to support key milestones through 2028, and they are exploring various financing and partnership options for their assets.
Temporary Mobile CVS Pharmacy Helps Restore Pharmacy Access in Pawling, NY, Following Fire
CVS Pharmacy has opened a temporary mobile pharmacy in Pawling, NY, just weeks after a fire destroyed its East Main Street store, restoring essential pharmacy access to the community. This temporary solution, located at the former store's site, allows residents to fill prescriptions and receive medication management services while plans for a permanent location progress. Additionally, CVS Health has donated $5,000 to Pawling Yoga & Wellness, a neighboring non-profit also affected by the fire, to support its rebuilding efforts.
Got prescriptions at Kroger? You may qualify for payment in $17 million proposed settlement
Kroger has reached a proposed $17 million settlement in a class action lawsuit alleging the grocer overcharged customers for generic prescription medications. Customers who filled prescriptions at Kroger-owned stores using insurance between December 9, 2018, and August 23, 2026, may qualify for a payment. Claims can be filed online until December 21, 2026, with payouts calculated proportionally based on the amount paid by the claimant and the total number of authorized claims.
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
Niagen Bioscience has expanded the retail availability of its Tru Niagen® supplement, now offering it at GNC and Sam's Club stores and online. This move strengthens the company's retail presence and makes the NAD-boosting healthy-aging supplement accessible to a broader consumer base across 44 states. Tru Niagen® is supported by extensive clinical studies and patents, affirming its scientific backing and quality standards.
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
Niagen Bioscience announced that its Tru Niagen® healthy aging supplement is now available at nearly 300 GNC and Sam’s Club locations across 44 states and online. This expansion includes Tru Niagen Beauty at GNC and various Tru Niagen 300mg bottle counts at both retailers, significantly strengthening its retail presence. The move reflects growing consumer demand for science-backed healthy aging solutions, leveraging Tru Niagen's clinically proven NAD+ boosting capabilities.
Westport Asset Management Inc. Makes New $1.84 Million Investment in CVS Health Corporation $CVS
Westport Asset Management Inc. has initiated a new $1.84 million investment in CVS Health Corporation, purchasing 17,772 shares during the second quarter. Other institutional investors also adjusted their holdings, with 80.66% of CVS's stock now owned by institutional investors. Analysts maintain a "Moderate Buy" rating for CVS, which recently exceeded quarterly earnings and revenue expectations and offers a 2.8% annual dividend yield.
United Bank Invests $2.25 Million in CVS Health Corporation $CVS
United Bank recently acquired a new position in CVS Health Corporation, purchasing 21,751 shares valued at approximately $2.25 million during the second quarter. This investment comes as several other institutional investors have also adjusted their holdings in CVS Health, which has a "Moderate Buy" consensus rating from analysts with an average target price of $107.17. CVS Health reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $0.665 per share.
17,720 Shares in CVS Health Corporation $CVS Acquired by Foster & Motley Inc.
Foster & Motley Inc. recently acquired 17,720 shares of CVS Health Corporation, valued at approximately $1.83 million. This comes as other institutional investors have also adjusted their holdings in the pharmacy operator. CVS Health reported strong quarterly earnings and announced a dividend, while analysts maintain a "Moderate Buy" consensus rating with an average price target of $107.17.
CVS Health Corp. stock underperforms Wednesday when compared to competitors
CVS Health Corp. stock dropped 1.33% to $93.65 on Wednesday, underperforming the broader market which saw the S&P 500 and Dow Jones Industrial Average rise. The company's stock closed 15.39% below its 52-week high of $110.68, achieved on July 22nd. This performance occurred despite an overall positive trading session for the stock market.
Tenet Healthcare (NYSE:THC) Stock Price
Tenet Healthcare (NYSE:THC) is currently trading at US$268.52, with a fair value estimate of US$250, indicating it is overvalued by 7.4%. Analyst narratives provide varying perspectives, with some highlighting growth drivers like behavioral care and outpatient trends, while others caution about M&A risks and Medicaid reliance. Recent insider transactions show net selling activity.
Should Stronger 2026 Guidance and New Board Expertise Require Action From Privia Health Group (PRVA) Investors?
Privia Health Group (PRVA) recently reported strong Q2 2026 results, raising its full-year revenue outlook and appointing an experienced healthcare executive, Dr. Opella Ernest, to its Board. This positive guidance and new expertise could significantly influence the company's long-term investment narrative, especially in scaling its value-based care model. Investors should consider these developments while also weighing potential risks like rising healthcare labor and technology costs.
Oracle Health Expands Clinical AI Agent with Automated Coding, Dictation, and Chart Review
Oracle Health has enhanced its Clinical AI Agent with new capabilities in the U.S. that include automated professional fee coding, direct dictation for clinicians, and AI-powered chart review. These advancements aim to streamline clinical documentation, improve revenue cycle workflows, and provide relevant patient context to help healthcare organizations operate more efficiently and allow clinicians to focus on patient care. The company reports that its AI agent has already saved physicians over 400,000 hours in note generation.
How CVS Specialty helps patients overcome barriers to care
CVS Specialty is addressing patient barriers to care by connecting individuals with community resources that tackle social determinants of health (SDOH), such as housing and nutrition. Through their CareTeams, clinicians like Diane Brighton visit patients at home to identify needs beyond medical charts and use a resource connection platform to link them with appropriate community organizations. This personalized, holistic approach aims to reduce obstacles to staying on therapy and improve long-term health outcomes for patients with chronic conditions.
CVS Health and Aetna Help Florida City Families Prepare for the School Year at Branches' Back to School Night
CVS Health and Aetna partnered with Branches Florida City to host a Back to School Night, providing over 250 students and their families with backpacks, school supplies, and hygiene kits. CVS Health also made a $100,000 donation to Branches to support its programs. The event aimed to prepare children for the new school year and foster community spirit with various family activities.
CVS Health and Aetna Help Florida City Families Prepare for the School Year at Branches' Back to School Night
CVS Health and Aetna partnered with Branches in Florida City to host a Back to School Night, providing over 250 students and their families with essential school supplies, hygiene kits, and a celebratory evening. CVS Health also donated $100,000 to Branches to support its ongoing programs for children and families. This initiative aims to ensure students are well-prepared for the academic year and to alleviate back-to-school financial burdens for families.
CVS Health (NYSE:CVS) Given New $114.00 Price Target at Argus
Argus has increased its price target for CVS Health (NYSE:CVS) to $114.00 from $104.00, reiterating a "buy" rating, indicating a potential upside of nearly 20%. This positive sentiment is echoed by other analysts, with a consensus "Moderate Buy" rating and an average price target of $107.17. The company recently reported strong quarterly earnings, exceeding analyst expectations for both EPS and revenue.
Meeder Advisory Services Inc. Takes Position in CVS Health Corporation $CVS
Meeder Advisory Services Inc. has acquired a new stake in CVS Health Corporation, purchasing 24,886 shares valued at approximately $2.574 million. This comes as other institutional investors have also adjusted their positions in the company, which recently reported strong Q2 results, increased its operating income outlook, and appointed a new board member to support AI initiatives. CVS Health maintains a "Moderate Buy" rating from analysts, with several increasing their price targets.
190,044 Shares in CVS Health Corporation $CVS Bought by Wealthfront Advisers LLC
Wealthfront Advisers LLC has acquired a new position in CVS Health Corporation, purchasing 190,044 shares valued at approximately $19.66 million during the second quarter. This move comes as CVS reported strong Q2 results, exceeding analyst expectations with EPS of $2.58 and revenue of $106.1 billion, leading to a raised 2026 operating income outlook. The company also maintains a "Moderate Buy" rating from analysts with a consensus price target of $106.75 and a quarterly dividend of $0.665 per share.
Great Lakes Advisors LLC Makes New Investment in CVS Health Corporation $CVS
Great Lakes Advisors LLC has acquired a new stake of 98,261 shares in CVS Health Corporation, valued at approximately $10.17 million. This investment comes as CVS Health reported strong second-quarter earnings, beating analyst estimates with an EPS of $2.58 and revenue of $106.1 billion, and raised its fiscal 2026 adjusted operating income outlook. Institutional investors collectively own 80.66% of CVS Health, which maintains a "Moderate Buy" consensus rating from analysts with an average price target of $106.75 and offers an annualized dividend yield of 2.8%.
Danske Bank A S Buys Shares of 890,499 CVS Health Corporation $CVS
Danske Bank A S has acquired a significant new position in CVS Health Corporation, purchasing 890,499 shares valued at approximately $92.1 million. This investment comes as CVS Health reported strong second-quarter results, exceeding revenue and EPS expectations, and raised its 2026 adjusted operating income outlook. Analysts maintain a "Moderate Buy" rating for CVS, with institutional investors collectively owning over 80% of the company's stock.
Aljian Capital Management LLC Takes Position in CVS Health Corporation $CVS
Aljian Capital Management LLC has acquired a new stake in CVS Health Corporation, purchasing 13,176 shares valued at approximately $1.36 million. This comes as CVS Health shows positive momentum with strong Q2 results, an increased operating income outlook, and a "Moderate Buy" consensus rating from analysts with an average price target of $106.75. The company also recently announced a quarterly dividend of $0.665 per share.
Winners And Losers Of Q2: McKesson (NYSE:MCK) Vs The Rest Of The Healthcare Providers & Services Stocks
This article analyzes the Q2 performance of healthcare providers and services stocks, highlighting top performers like McKesson and CVS Health, and the weakest, AdaptHealth. It discusses the sector's general trends, including consistent demand versus high operational costs and regulatory pressures, while also touching upon broader market risks like AI and geopolitics.
Soon you can buy Medicare Advantage plans at Costco. What you need to know.
Costco Wholesale is expanding its offerings by partnering with nonprofit insurer SCAN Group to sell jointly branded Medicare Advantage and Medicare supplement plans. This move makes Costco the latest consumer brand to venture into offering health insurance options. The new plans will be available alongside Costco's existing wide range of products and services.
Every community deserves a healthier heart
Heart disease remains the leading cause of death in the nation, disproportionately affecting underserved communities due to factors like limited healthcare access and social determinants of health. Addressing these disparities requires population-specific solutions that combine improved access to care with education, engagement, and social support. CVS Health emphasizes understanding community-specific barriers and implementing tailored approaches to help individuals identify risk, connect to care, and remain engaged in their health journey for better outcomes.
How Should You Approach CVS Health Stock After Q2 Earnings?
CVS Health reported strong Q2 2026 results with significant revenue and adjusted operating income growth across all segments, leading management to raise its full-year outlook for adjusted EPS and cash flow. Despite the strong performance and outperformance against benchmarks and peers over the last 12 months, the stock saw a 5.1% dip after earnings. The company faces near-term challenges with its Caremark 340B business and potential membership declines but maintains an attractive valuation, suggesting existing shareholders might hold, while new investors may seek a better entry point.
Pzena Investment Management LLC Takes Position in CVS Health Corporation $CVS
Pzena Investment Management LLC has acquired a significant new position in CVS Health Corporation (NYSE:CVS), purchasing over 11.77 million shares valued at approximately $1.22 billion, making it their fourth-largest holding. This comes as CVS reported strong quarterly earnings, beating analyst estimates with $2.58 EPS and $106.1 billion in revenue, alongside maintaining an annualized dividend of $2.66 per share. Analysts have largely maintained a "Moderate Buy" rating for CVS with a consensus target price of $106.75, despite the stock recently trading down.
Trust Co. of Vermont Acquires New Stake in CVS Health Corporation $CVS
Trust Co. of Vermont has acquired a new stake in CVS Health Corporation, purchasing 28,800 shares valued at approximately $2.979 million in the second quarter. Other institutional investors also adjusted their holdings in CVS. Analysts have set new price targets, with a consensus "Moderate Buy" rating and an average target price of $106.75 for CVS Health.
Focused Alpha LLC Makes New $1.34 Million Investment in CVS Health Corporation $CVS
Focused Alpha LLC has initiated a new position in CVS Health Corporation (NYSE:CVS) during the second quarter, purchasing 12,923 shares valued at approximately $1.34 million. This investment comes amidst other institutional investor activity, including large stakes acquired by BlackRock Inc., Vanguard Group Inc., and State Street Corp. Analysts generally rate CVS Health as a "Moderate Buy" with an average target price of $106.75, following recent upward revisions to price objectives.
Deutsche Bank AG Takes $466.63 Million Position in CVS Health Corporation $CVS
Deutsche Bank AG has acquired a new position in CVS Health Corporation, purchasing over 4.5 million shares valued at approximately $466.63 million in the second quarter, representing about 0.35% of CVS Health. This move comes as other institutional investors have also adjusted their holdings in CVS, while a company director recently sold a significant number of shares. CVS Health reported strong quarterly earnings, exceeding analyst expectations, and announced a quarterly dividend.
BlackRock Inc. Buys Shares of 123,223,409 CVS Health Corporation $CVS
BlackRock Inc. has purchased 123,223,409 shares of CVS Health Corporation, valued at approximately $12.75 billion, representing about 9.66% ownership. This comes as other institutional investors have also adjusted their stakes, while a director recently sold a significant number of shares. Analysts currently rate CVS Health as a "Moderate Buy" with an average target price of $106.75, following recent strong earnings and a declared quarterly dividend.
CVS Health (CVS) Announces Board Resignation and Appointment of JPMorgan Executive
CVS Health has announced changes to its Board of Directors, with Larry M. Robbins resigning effective August 13, 2026. Teresa Heitsenrether, Executive Vice President and Chief Data & Analytics Officer at JPMorgan Chase & Co., will join the Board on November 18, 2026. Her appointment is expected to support CVS Health's continued digital transformation in healthcare delivery.
CVS Health Corp. stock underperforms Monday when compared to competitors
CVS Health Corp. stock experienced a 3.24% decline on Monday, closing at $94.01. This underperformance occurred during a generally negative trading session, with both the S&P 500 and Dow Jones Industrial Average also seeing drops. The fall ended a three-day winning streak for CVS Health.
JPMorgan’s data chief will join CVS Health’s board this fall
CVS Health announced that Teresa Heitsenrether, Chief Data & Analytics Officer at JPMorgan Chase, will join its Board of Directors effective November 18, 2026. She brings extensive experience in data, analytics, artificial intelligence, and operational transformation, aligning with CVS Health's strategy to become a consumer-focused health technology company. Concurrently, Larry Robbins departed the board on August 13, 2026, after two years of service.
Kroger Health president Colleen Lindholz to keynote GLP-1 Shopper Summit
Colleen Lindholz, president of Kroger Health, will deliver the opening keynote at the inaugural GLP-1 Shopper Summit on November 12. Her keynote, "Reimagining Food as Health," will explore the intersection of food, nutrition, and healthcare, focusing on how retailers can facilitate healthier choices for consumers, especially with the growing adoption of GLP-1 medications. The summit will examine how these trends are reshaping shopper behavior and future growth strategies for retail and CPG industries.
Robbins LLP Urges SPRY Stockholders Who Lost Money Investing in ARS Pharmaceuticals Inc. to Contact the Firm for Information About Leading the Class Action Lawsuit
Robbins LLP is urging stockholders of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) who incurred losses to contact the firm regarding a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made misleading statements about the timeline for expanded insurance coverage of its epinephrine nasal spray, neffy, with CVS Caremark. The stock price declined significantly after it was revealed that the expected coverage by July 1, 2026, did not materialize, leading to a drop of over 23.9% in one day.
